Trial Profile
A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acral lentiginous melanoma; Brain metastases; Malignant melanoma; Skin cancer; Uveal melanoma
- Focus Therapeutic Use
- Acronyms ADAPT-IT
- 06 Jun 2023 Results (n=60) reporting final clinical analysis, including median progression-free survival (PFS) and first correlative analysis of blood-based biomarkers of response in patients with unresectable melanoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 03 Apr 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 03 Apr 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.